Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 ...

CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations ...

The acquisition will give Incyte two dermatology drugs currently being investigated for several inflammatory skin diseases.

Incyte (NASDAQ:INCY) has agreed to acquire Escient Pharmaceuticals, a privately held biotech focused on developing ...

Incyte has agreed to acquire US-based Escient Pharmaceuticals and its assets including two first-in-class small molecule ...

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists ...

Incyte says the firm it is acquiring has new drug candidates representing multibillion-dollar revenue opportunities.

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with ...

Incyte said it will pay $750 million to buy San Diego biotech Escient Pharmaceuticals and its pipeline of early-stage drug ...

AdvertisementIncyte has agreed to acquire Escient Pharmaceuticals, a clinical-stage company with a promising dermatology ...

Incyte Corp. (INCY) announced that it has entered into a definitive agreement to acquire Escient Pharmaceuticals (a private company) for $750 million. The company’s key drug development candidates ...

By Colin Kellaher Incyte has struck a deal to buy clinical-stage drug discovery and development company Escient Pharmaceuticals for $750 million. Incyte ...